New Published Research from the Gastric Cancer Registry Team
Our Gastric Cancer Registry project at Stanford is leading to important research and new discoveries. A recently published study used... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Foundation Funds Major Expansion of Gastric Cancer Registry
The Gastric Cancer Foundation has committed $257,856 to fund a transformative expansion of the Gastric Cancer Registry in 2021. The... Read More
Blood test picks out cancers likely to benefit from targeted drugs
British researchers discovered that a blood test could identify gastric cancer patients who might benefit from EGFR-inhibiting drugs.Gastric Cancer Registry Prepares to Launch Innovative Data Portal
The Gastric Cancer Registry is the first comprehensive repository of clinical and genomic data pertaining to stomach cancer. Its chief... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer... Read More
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
Singapore Clinicians and Scientists Achieve Big Leap in Early Diagnosis of Gastric Cancer Through the Development of Non-Invasive Blood-based Test
Researchers in Singapore have developed a blood test that they believe could be used for early detection of gastric cancer.
UArizona Health Sciences Researchers Find Biomarker that Can Appear Before Stomach Cancer Develops
Researchers at the University of Arizona discovered a biomarker that appears in people before stomach cancer develops and that can... Read More
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with... Read MoreFoundation-Funded Lab at MD Anderson Advances Discoveries in Peritoneal Carcinomatosis
About 45% of gastric cancer patients experience peritoneal carcinomatosis (PC), the spread of the cancer to the abdominal lining—a development... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.-
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and... Read More 
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction... Read MoreNew Grant Awarded to USC for Study of Epigenetic Targets in Gastric Cancer
Some gastric tumors have genetic abnormalities that can be directly targeted with drugs, such as HER2 mutations. But cancer is... Read MoreNew Foundation Grant to Dana-Farber for Study of “Chromosomal Instability” in Gastric Cancer
Gastric tumors with a genetic abnormality called microsatellite instability-high (MSI-H) can be treated with immune-targeted drugs, but there’s a much... Read More
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Basilea Pharmaceutica has started a study of a drug that inhibits the cancer-driving protein FGFR. It will be studied alone... Read More
Association of malnutrition with geriatric assessment impairments and health‐related quality of life among older adults with gastrointestinal malignancies
Gastric cancer patients over age 60 face a high risk of malnutrition, which lowers their quality of life and leads... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.